Stock listing
Lang & Schwarz:862449 Bio-Rad Laboratories, Inc. Aktie
German listing (Lang & Schwarz) of Bio-Rad Laboratories, Inc. · home listing NYSE:BIO
Follow Bio-Rad Laboratories, Inc. into a list and get an email when it puts out news.
Home listing price · NYSE:BIO
$358.90 USD -11.27 (-3.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NYSE:BIO
- Day range
- $353.31 – $369.44 USDNov 20, 2026
- Volume
- 182,296 sharesNov 20, 2026
- Market cap
- $7.84B USDAt the close on Nov 20, 2026 · price × 21.83M shares outstanding
- 52-week range
- $236.73 – $396.23 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $96.59M USDMedian day 251,320 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:BIO · Home | $358.90 USD | -11.27 (-3.0%) | 182,296 | $364.34 | $369.44 | $353.31 | $370.17 | Close on Nov 20, 2026 |
| NYSE:BIO.B | $389.98 USD | +10.48 (+2.8%) | 154 | $389.98 | $389.98 | $389.98 | $379.50 | Close on Nov 9, 2026 |
| Frankfurt:BUWA | €325.40 EUR | -10.80 (-3.2%) | — | €330.80 | €330.80 | €323.20 | €336.20 | Close on Nov 20, 2026 |
| Frankfurt:BUW | €304.00 EUR | 0.00 (0.0%) | — | €304.00 | €304.00 | €304.00 | €304.00 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:BIO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $358.90 | -11.27 | -3.0% | $364.34 | $369.44 | $353.31 | 182,296 | |
| $370.17 | +11.98 | +3.3% | $358.00 | $370.65 | $358.00 | 460,451 | |
| $358.19 | -2.07 | -0.6% | $359.39 | $361.69 | $356.58 | 202,626 | |
| $360.26 | -6.10 | -1.7% | $363.83 | $365.61 | $358.64 | 169,935 | |
| $366.36 | -4.12 | -1.1% | $370.19 | $373.50 | $364.11 | 255,113 | |
| $370.48 | -15.52 | -4.0% | $382.88 | $389.98 | $369.40 | 182,297 | |
| $386.00 | -0.48 | -0.1% | $388.31 | $389.61 | $382.76 | 212,180 | |
| $386.48 | -1.83 | -0.5% | $386.92 | $390.44 | $381.77 | 210,957 | |
| $388.31 | +6.74 | +1.8% | $385.38 | $394.73 | $381.59 | 547,366 | |
| $381.57 | +12.57 | +3.4% | $364.45 | $384.62 | $363.59 | 273,122 | |
| $369.00 | -10.99 | -2.9% | $367.29 | $375.07 | $352.09 | 433,887 | |
| $379.99 | +5.08 | +1.4% | $380.05 | $382.00 | $371.85 | 281,796 | |
| $374.91 | +8.75 | +2.4% | $369.45 | $376.81 | $369.45 | 214,401 | |
| $366.16 | -6.02 | -1.6% | $374.79 | $377.90 | $361.27 | 211,830 | |
| $372.18 | -12.22 | -3.2% | $381.09 | $381.29 | $368.45 | 183,084 | |
| $384.40 | -0.72 | -0.2% | $389.15 | $390.00 | $379.24 | 332,334 | |
| $385.12 | +4.13 | +1.1% | $384.15 | $388.86 | $380.17 | 251,320 | |
| $380.99 | +8.56 | +2.3% | $376.25 | $381.87 | $369.41 | 167,153 | |
| $372.43 | +2.48 | +0.7% | $371.80 | $376.00 | $369.76 | 179,098 | |
| $369.95 | +6.45 | +1.8% | $356.98 | $371.31 | $352.46 | 167,404 | |
| $363.50 | +3.00 | +0.8% | $359.83 | $367.93 | $359.83 | 228,223 | |
| $360.50 | +6.00 | +1.7% | $350.21 | $362.42 | $347.29 | 360,455 | |
| $354.50 | +1.68 | +0.5% | $352.08 | $356.93 | $350.49 | 212,450 | |
| $352.82 | -0.88 | -0.2% | $355.30 | $356.34 | $350.61 | 220,861 | |
| $353.70 | -11.12 | -3.0% | $369.37 | $369.37 | $350.77 | 207,700 | |
| $364.82 | +2.39 | +0.7% | $364.90 | $368.54 | $359.88 | 247,800 | |
| $362.43 | -1.30 | -0.4% | $367.86 | $371.07 | $361.27 | 297,400 | |
| $363.73 | -0.69 | -0.2% | $369.00 | $369.43 | $358.43 | 132,600 | |
| $364.42 | -1.74 | -0.5% | $369.85 | $369.85 | $359.41 | 181,100 | |
| $366.16 | +5.76 | +1.6% | $364.32 | $368.67 | $361.32 | 139,000 | |
| $360.40 | -7.52 | -2.0% | $371.99 | $372.59 | $353.97 | 312,000 | |
| $367.92 | -0.91 | -0.2% | $373.16 | $374.60 | $363.98 | 251,900 | |
| $368.83 | -10.99 | -2.9% | $383.38 | $390.00 | $367.49 | 162,538 | |
| $379.82 | +10.68 | +2.9% | $368.07 | $381.78 | $363.96 | 279,402 | |
| $369.14 | +13.57 | +3.8% | $357.28 | $369.40 | $357.28 | 223,600 | |
| $355.57 | -22.14 | -5.9% | $373.87 | $379.67 | $353.30 | 264,600 | |
| $377.71 | -1.84 | -0.5% | $377.61 | $380.88 | $374.02 | 228,600 | |
| $379.55 | +1.86 | +0.5% | $377.73 | $381.56 | $374.79 | 261,700 | |
| $377.69 | -3.31 | -0.9% | $376.98 | $383.95 | $373.18 | 272,600 | |
| $381.00 | -6.54 | -1.7% | $384.14 | $387.00 | $376.43 | 253,600 | |
| $387.54 | +8.66 | +2.3% | $377.73 | $389.38 | $376.18 | 374,200 | |
| $378.88 | -0.69 | -0.2% | $379.27 | $382.85 | $374.77 | 177,200 | |
| $379.57 | +2.24 | +0.6% | $377.53 | $383.25 | $374.01 | 374,700 | |
| $377.33 | +0.92 | +0.2% | $381.58 | $381.58 | $373.47 | 311,500 | |
| $376.41 | -6.00 | -1.6% | $383.05 | $383.05 | $374.81 | 324,347 | |
| $382.41 | +3.38 | +0.9% | $384.23 | $385.71 | $377.69 | 205,000 | |
| $379.03 | +1.03 | +0.3% | $378.25 | $385.33 | $375.00 | 262,400 | |
| $378.00 | +9.45 | +2.6% | $366.33 | $380.91 | $366.28 | 519,131 | |
| $368.55 | -0.77 | -0.2% | $365.66 | $370.52 | $365.66 | 292,990 | |
| $369.32 | +0.57 | +0.2% | $370.45 | $373.71 | $368.69 | 344,800 | |
| $368.75 | -8.22 | -2.2% | $379.92 | $382.01 | $368.56 | 334,400 | |
| $376.97 | -3.15 | -0.8% | $380.00 | $380.06 | $373.34 | 177,000 | |
| $380.12 | -5.99 | -1.6% | $390.73 | $390.73 | $379.49 | 138,800 | |
| $386.11 | -1.79 | -0.5% | $380.84 | $386.78 | $376.20 | 112,900 | |
| $387.90 | -0.61 | -0.2% | $390.00 | $394.29 | $381.06 | 148,000 | |
| $388.51 | +7.55 | +2.0% | $380.62 | $389.83 | $380.23 | 285,333 | |
| $380.96 | -5.16 | -1.3% | $387.88 | $387.88 | $380.27 | 256,110 | |
| $386.12 | -1.58 | -0.4% | $393.85 | $394.02 | $382.13 | 301,423 | |
| $387.70 | -2.24 | -0.6% | $390.82 | $392.29 | $382.10 | 207,000 | |
| $389.94 | +1.30 | +0.3% | $389.03 | $396.23 | $386.69 | 245,900 | |
| $388.64 | -1.70 | -0.4% | $393.10 | $393.10 | $385.50 | 221,700 | |
| $390.34 | +8.58 | +2.2% | $384.00 | $390.83 | $377.80 | 295,718 | |
| $381.76 | +1.73 | +0.5% | $384.09 | $384.09 | $373.40 | 300,154 | |
| $380.03 | +3.57 | +0.9% | $385.80 | $385.92 | $373.47 | 341,200 | |
| $376.46 | +12.20 | +3.3% | $360.29 | $380.71 | $360.25 | 337,500 |
Splits
5 splits since 1980 · NYSE:BIO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split | |
| 3-for-2 | Split | |
| 3-for-2 | Split | |
| 3-for-2 | Split | |
| 2-for-1 | Split |
- Ticker
- Lang & Schwarz:862449
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 4, 2026
Bio-Rad Reports Third-Quarter 2026 Financial Results
Latest earnings call · Nov 4, 2026
Bio-Rad Laboratories (NYSE:BIO) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Q3 2026 Earnings Presentation
Earnings · 16 slides
Latest news
Bio-Rad Reports Third-Quarter 2026 Financial Results
Nov 4, 2026
Closed $369.00 (-2.9%) on Nov 5, 2026
Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
Oct 29, 2026
Closed $372.18 (-3.2%) on Oct 30, 2026
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
Oct 14, 2026
Closed $362.43 (-0.4%) on Oct 14, 2026
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
Sep 16, 2026
Closed $379.03 (+0.3%) on Sep 16, 2026
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference
Aug 31, 2026
Closed $386.12 (-0.4%) on Aug 31, 2026
Bio-Rad Reports Second-Quarter 2026 Financial Results
Aug 4, 2026
Closed $347.86 (+4.5%) on Aug 5, 2026
Bio-Rad to Participate in Upcoming Investor Conferences
May 8, 2026
Closed $254.32 (-1.2%) on May 8, 2026
Bio-Rad Reports First-Quarter 2026 Financial Results
Apr 30, 2026
Closed $256.55 (-8.4%) on May 1, 2026
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
Apr 16, 2026
Closed $299.02 (+2.7%) on Apr 17, 2026
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
Feb 12, 2026
Closed $256.56 (-12.3%) on Feb 13, 2026
Bio-Rad Laboratories, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 12 in the last 12 months · 26 in all · newest Nov 4, 2026 · oldest 2025
- Calls
- 32 calls with a replay · 32 with a transcript · latest Nov 4, 2026
- Decks
- 24 decks · latest Nov 4, 2026
Where Bio-Rad Laboratories, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE:BIO · Home listing | NYSE | United States | USD |
| NYSE:BIO.B | NYSE | United States | USD |
| BOATS:BIO | BOATS | United States | USD |
| gettex:BUWA | gettex | Germany | EUR |
| LS Exchange:865406 | LS Exchange | Germany | EUR |
| Lang & Schwarz:865406 | Lang & Schwarz | Germany | EUR |
| Tradegate:BUWA | Tradegate | Germany | EUR |
| BOATS:BIO.B | BOATS | United States | USD |
| Frankfurt:BUWA | Frankfurt | Germany | EUR |
| Stuttgart:BUWA | Stuttgart | Germany | EUR |
| Dusseldorf:BUWA | Dusseldorf | Germany | EUR |
| Frankfurt:BUW | Frankfurt | Germany | EUR |
| Munich:BUWA | Munich | Germany | EUR |
| Lang & Schwarz:862449 · This page | Lang & Schwarz | Germany | EUR |
| LS Exchange:862449 | LS Exchange | Germany | EUR |
Valuation
P/E 7.7× against a median of 38.4×: the lowest of 6 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $7.38B USD
- P/E
- 7.7×
- EV/sales
- 2.8×
- EV/EBITDA
- 71.0×
- Price/book
- 1.0×
- Gross margin
- 51.3%
- Operating margin
- −2.4%
- Net margin
- 39.5%
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 0.72
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. · NYSE:BIO | US$7.84B | US$7.38B | 7.7× | 2.8× | 71.0× | 1.0× | 39.5% | 0.2× | 0.72 |
| WuXi XDC Cayman, Inc. · HKEX:2268 | US$9.64B | US$8.87B | 43.5× | 10.0× | 33.5× | 5.7× | 24.9% | 0.1× | n/a |
| Tempus AI, Inc. · NASDAQ:TEM | US$9.58B | US$8.99B | n/a | 6.0× | n/a | 19.1× | −12.5% | 0.0× | 2.51 |
| Bruker Corporation · NASDAQ:BRKR | US$8.62B | US$10.22B | n/a | 2.9× | 64.4× | 3.7× | −3.5% | 0.7× | 1.72 |
| Pharmaron Beijing Co., Ltd. Class A · SZSE:300759 | US$8.52B | US$8.23B | 32.1× | 3.4× | n/a | 3.4× | 11.1% | 0.1× | n/a |
| GenScript Biotech Corporation · HKEX:1548 | US$8.08B | US$7.50B | n/a | 7.8× | 22.8× | 2.1× | −55.5% | 0.1× | n/a |
| Shenzhen New Industries Biomedical Engineering Co. Ltd. Class A · SZSE:300832 | US$7.51B | US$7.10B | 27.8× | 9.8× | n/a | 5.3× | 37.2% | 0.0× | n/a |
| Twist Bioscience Corporation · NASDAQ:TWST | US$7.04B | US$6.46B | n/a | 14.1× | n/a | 7.9× | −28.3% | 0.0× | 2.77 |
| Asymchem Laboratories (Tianjin) Co., Ltd. Class A · SZSE:002821 | US$6.83B | US$5.89B | 38.5× | 5.3× | n/a | 2.6× | 15.9% | 0.0× | n/a |
| Bachem Holding AG Class B · SIX:BANB | US$6.80B | US$6.99B | 38.4× | 8.4× | 29.7× | 4.0× | 21.4% | 0.1× | n/a |
| 10x Genomics, Inc. · NASDAQ:TXG | US$6.29B | US$5.79B | n/a | 9.4× | n/a | 7.5× | −10.8% | 0.1× | 2.34 |
| Median of the others | US$7.79B | US$7.30B | 38.4× | 8.1× | 31.6× | 4.6× | 3.8% | 0.1× | 2.42 |
Forecasts
1 buy · 1 hold · 1 sell · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 356.67 USD · Analysts' mean
- EPS, year to Dec 2026
- 9.61 · 3 analysts
- Revenue, year to Dec 2026
- 2.57B · 3 analysts
Team and board
| Officer | Role |
|---|---|
| Norman Schwartz | CEO |
| Anna Gralinska | Corporate Communications |
| Edward Chung | Investor Relations |
| Ruben Argueta | Investor Relations |
Events
Calls
| Call | When | Status |
|---|---|---|
| Bio-Rad Laboratories (NYSE:BIO) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 5:00 PM ET | Replay |
| Bio-Rad Laboratories (NYSE:BIO) Q2 2026 Earnings Call | Tue, Aug 04, 2026 · 5:00 PM ET | Replay |
| Bio-Rad Laboratories (NYSE:BIO) Q1 2026 Earnings Call | Thu, Apr 30, 2026 · 5:00 PM ET | Replay |
| Bio-Rad Laboratories (NYSE:BIO) Q4 2025 Earnings Call | Thu, Feb 12, 2026 · 5:00 PM ET | Replay |
| Bio-Rad Laboratories (NYSE:BIO) Q3 2025 Earnings Call | Wed, Oct 29, 2025 · 5:00 PM ET | Replay |
| Bio-Rad Laboratories (NYSE:BIO) Q2 2025 Earnings Call | Thu, Jul 31, 2025 · 5:00 PM ET | Replay |
| Bio-Rad Laboratories (NYSE:BIO) Q1 2025 Earnings Call | Thu, May 01, 2025 · 5:30 PM ET | Replay |
| Bio-Rad Laboratories (NYSE:BIO) Q4 2024 Earnings Call | Thu, Feb 13, 2025 · 5:00 PM ET | Replay |
| Bio-Rad Laboratories (NYSE:BIO) Q3 2024 Earnings Call | Wed, Oct 30, 2024 · 5:00 PM ET | Replay |
| Bio-Rad Laboratories (NYSE:BIO) Q2 2024 Earnings Call | Thu, Aug 01, 2024 · 5:00 PM ET | Replay |
All 32 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −2.9% |
| Q2 2026 | Aug 4, 2026 · After close | +4.5% |
| Q1 2026 | Apr 30, 2026 · After close | −8.4% |
| Q4 2025 | Feb 12, 2026 · After close | −12.3% |
| Q3 2025 | Oct 29, 2025 · After close | −4.7% |
| Q2 2025 | Jul 31, 2025 · After close | +17.6% |
| Q1 2025 | May 1, 2025 · After close | −1.7% |
| Q4 2024 | Feb 13, 2025 · After close | −9.5% |
| Q3 2024 | Oct 30, 2024 · After close | +8.3% |
| Q2 2024 | Aug 1, 2024 · After close | −1.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | −4.2% |
| Q4 2023 | Feb 15, 2024 · After close | +3.6% |
| Q3 2023 | Oct 26, 2023 · After close | −7.2% |
| Q2 2023 | Aug 3, 2023 · After close | −0.5% |
| Q1 2023 | May 4, 2023 · After close | −16.7% |
| Q4 2022 | Feb 16, 2023 · After close | +6.0% |
| Q3 2022 | Oct 27, 2022 · After close | −8.0% |
| Q2 2022 | Jul 28, 2022 · After close | +0.6% |
| Q1 2022 | Apr 28, 2022 · After close | −0.2% |
| Q4 2021 | Feb 10, 2022 · After close | +0.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 16 slides | Nov 4, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 18 slides | Aug 4, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 18 slides | Apr 30, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 26 slides | Feb 12, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 17 slides | Oct 29, 2025 |
| Bio-Rad's Droplet Digital PCR Webinar (August 2025) | Conference | 18 slides | Aug 26, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 15 slides | Jul 31, 2025 |
| Investor Presentation (February 2024) | Investor deck | 96 slides | February 2024 |
| Jefferies Healthcare Conference 2023 | Conference | 18 slides | Jun 8, 2023 |
| J.P. Morgan Healthcare Conference 2023 | Conference | 26 slides | Jan 10, 2023 |
All 24 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| J.P. Morgan 41st Annual Healthcare Conference 2023 | Conference | 26 slides | Jan 10, 2023 |
| Technical Presentation (2023) | Technical | 80 slides | 2023 |
| Technical Presentation (2022) | Technical | 129 slides | Dec 14, 2022 |
| Investor Day (February 2022) | Investor day | 102 slides | Feb 25, 2022 |
| Investor Day (December 2020) | Investor day | 12 slides | Dec 10, 2020 |
| Technical Presentation (2020) | Technical | 47 slides | 2020 |
| Technical Presentation (2020) | Technical | 44 slides | 2020 |
| Jefferies 2019 Healthcare Conference | Conference | 26 slides | 2019 |
| Barclays Global Healthcare Conference 2018 | Conference | 23 slides | 2018 |
| Investor Presentation (September 2016) | Investor deck | 19 slides | Sep 9, 2016 |
| Investor Presentation (September 2015) | Investor deck | 56 slides | September 2015 |
| Investor Presentation (March 2013) | Investor deck | 20 slides | March 2013 |
| Technical Presentation (2007) | Technical | 22 slides | 2007 |
| 第二届国际分析技术博览会 (Analytica China 2004), Shanghai | Conference | 36 slides | September 2004 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.58B | 2.57B | 2.67B | 2.80B | 2.92B | 2.55B | 2.31B | 2.29B | 2.16B | 2.07B |
| Cost of revenue | 1.24B | 1.19B | 1.24B | 1.23B | 1.28B | 1.11B | 1.05B | 1.07B | 972.5M | 929.7M |
| Gross profit | 1.34B | 1.38B | 1.43B | 1.57B | 1.64B | 1.44B | 1.26B | 1.22B | 1.19B | 1.14B |
| Research and development | 275.6M | 295.9M | 247.4M | 256.9M | 260.6M | 217.8M | 202.7M | 199.2M | 250.2M | 205.7M |
| Selling, general and administrative | 844.3M | 814.0M | 841.7M | 827.8M | 877.1M | 798.8M | 824.6M | 834.8M | 806.8M | 814.7M |
| Operating income | 47.2M | 269.0M | 337.8M | 482.6M | 500.3M | 421.3M | 229.7M | -103.3M | 119.3M | 55.7M |
| Depreciation and amortization | 165.4M | 151.6M | 145.9M | 137.3M | 137.6M | 138.6M | 134.2M | 138.1M | 148.7M | 142.9M |
| EBITDA | 212.6M | 420.6M | 483.7M | 619.9M | 637.9M | 559.9M | 363.9M | 34.8M | 267.9M | 198.6M |
| Interest expense | 49.0M | 48.9M | 49.4M | 38.1M | 1.55M | 21.9M | 23.4M | 24.0M | 23.0M | 23.4M |
| Income before tax | 995.5M | -2.34B | -850.1M | -4.70B | 5.45B | 4.92B | 2.26B | 512.7M | 97.8M | 41.6M |
| Income tax | 235.6M | -498.3M | -212.8M | -1.08B | 1.19B | 1.10B | 502.4M | 147.0M | -24.4M | 15.6M |
| Net income | 759.9M | -1.84B | -637.3M | -3.63B | 4.25B | 3.81B | 1.76B | 365.6M | 122.2M | 26.0M |
| Earnings per share, basic | 27.87 | -65.36 | -21.82 | -121.79 | 142.61 | 128.13 | 58.93 | 12.25 | 4.12 | 0.88 |
| Earnings per share, diluted | 27.85 | -65.36 | -21.82 | -121.79 | 140.83 | 126.47 | 58.27 | 12.10 | 4.07 | 0.88 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 529.8M | 488.1M | 403.8M | 434.2M | 470.8M | 662.2M | 660.7M | 431.5M | 383.8M | 456.3M |
| Short-term investments | 1.01B | 1.18B | 1.20B | 1.36B | 399.1M | 328.9M | 454.0M | 413.3M | 371.2M | 383.2M |
| Receivables | 460.6M | 452.5M | 489.0M | 494.6M | 423.5M | 419.4M | 392.7M | 392.4M | 464.8M | 372.3M |
| Inventory | 740.7M | 760.0M | 780.5M | 719.3M | 572.2M | 622.3M | 554.0M | 583.8M | 594.8M | 525.0M |
| Current assets | 2.91B | 3.03B | 3.05B | 3.16B | 1.99B | 2.14B | 2.18B | 2.02B | 1.98B | 1.84B |
| Property, plant and equipment | 539.9M | 528.1M | 529.0M | 498.6M | 511.6M | 491.4M | 499.3M | 508.7M | 493.5M | 488.6M |
| Goodwill | 579.8M | 410.5M | 413.6M | 406.5M | 347.3M | 291.9M | 264.1M | 219.8M | 506.1M | 477.1M |
| Total assets | 10.6B | 9.36B | 12.3B | 13.5B | 17.8B | 13.0B | 8.01B | 5.61B | 4.27B | 3.85B |
| Accounts payable | 129.0M | 122.3M | 144.6M | 135.0M | 141.9M | 139.5M | 107.0M | 122.5M | 135.2M | 133.1M |
| Current liabilities | 517.0M | 467.8M | 522.8M | 568.7M | 680.9M | 631.5M | 905.5M | 450.8M | 502.7M | 471.3M |
| Long-term debt | 1.20B | 1.20B | 1.20B | 1.20B | 10.5M | 12.3M | 13.6M | 438.9M | 434.6M | 434.2M |
| Total debt | 1.20B | 1.20B | 1.21B | 1.20B | 10.5M | 12.3M | 13.6M | 438.9M | 435.0M | 434.5M |
| Total liabilities | 3.12B | 2.79B | 3.56B | 3.89B | 4.11B | 3.09B | 2.25B | 1.59B | 1.34B | 1.27B |
| Shareholders' equity | 7.45B | 6.57B | 8.74B | 9.62B | 13.7B | 9.89B | 5.76B | 4.02B | 2.93B | 2.58B |
| Shares outstanding | 27.3M | 28.2M | 29.2M | 29.8M | 30.2M | 30.2M | 30.2M | 30.2M | 30.0M | 29.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 532.2M | 455.2M | 374.9M | 194.4M | 669.5M | 585.0M | 457.9M | 285.5M | 104.1M | 216.1M |
| Capital spending | -157.6M | -165.6M | -156.7M | -112.8M | -133.7M | -108.6M | -98.5M | -129.8M | -111.3M | -141.4M |
| Free cash flow | 374.6M | 289.6M | 218.2M | 81.6M | 535.7M | 476.4M | 359.4M | 155.7M | -7.20M | 74.6M |
| Cash from investing | -189.7M | -160.2M | 20.2M | -1.21B | -797.4M | -69.9M | -208.9M | -187.0M | -175.6M | -213.9M |
| Cash from financing | -283.2M | -218.8M | -425.6M | 973.6M | -55.4M | -523.0M | -22.8M | -48.7M | 341.0K | 9.02M |
| Dividends paid | -100.1B | -68.2B | -35.3B | -20.2M | -3.83B | -4.37M | ||||
| Share buybacks | -295.5M | -203.6M | -428.7M | -215.7M | -50.0M | -100.0M | -28.0M | -48.9M | -2.92M | 0 |
| Change in cash | 42.4M | 85.4M | -30.1M | -36.6M | -196.0M | 4.46M | 228.5M | 49.2M | -72.4M | -1.28M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 9, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 28, 2026 | Other filings | SEC |
| SD · Specialized disclosure | May 13, 2026 | ESG report | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 11, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Apr 30, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Apr 30, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 30, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 24, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Mar 25, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 25, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 19, 2026 | Current report | SEC |
| 10-K · Annual report | Feb 12, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 12, 2026 | Results | SEC |
| 144 · Notice of proposed sale | Dec 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 6, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 29, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 28, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 28, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 30, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 26, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Aug 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 5, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Jul 31, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 28, 2025 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 18, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| SD · Specialized disclosure | May 20, 2025 | ESG report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 5, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 5, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 25, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Apr 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Mar 26, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 26, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 4, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 21, 2025 | Current report | SEC |
| 10-K · Annual report | Feb 14, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 20, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 8, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 6, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 31, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 25, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 24, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 22, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 22, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 10, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 10, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Sep 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 12, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 9, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | Sep 6, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 4, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 27, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 20, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 2, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 13, 2024 | Other filings | SEC |
| SD · Specialized disclosure | May 9, 2024 | ESG report | SEC |
| S-8 · Registration statement for employee plans | May 8, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 3 · Initial statement of ownership | May 8, 2024 | Insider trade | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 26, 2024 | Management or board change | SEC |
| SC 13G · Big-stake notice | Apr 22, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Apr 17, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 10, 2024 | Management or board change | SEC |
| DEF 14A · Proxy statement | Mar 27, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 27, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 28, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 27, 2024 | Other filings | SEC |
| 8-K · Current report | Feb 21, 2024 | Current report | SEC |
| 10-K · Annual report | Feb 16, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 15, 2024 | Results | SEC |
| 8-K · Current report | Feb 14, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 19, 2023 | Insider trade | SEC |
This page holds 200 of 1,002 filings. Open Filings
Cap table
Built by 6ix from Bio-Rad Laboratories, Inc.’s releases
- Common shares
- 21,832,130
- Fully diluted
- 21,832,130
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 21,832,130 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 21,832,130 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ted W Love Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 17, 2026); Jazz Pharmaceuticals plc (Director · Since at least Dec 1, 2025); Gilead Sciences, Inc. (Director · Since at least Feb 1, 2024); Structure Therapeutics, Inc. (Director · Since at least Aug 3, 2023); Royalty Pharma plc (Director · Since at least Jul 30, 2020); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Savara, Inc. (Director · Sep 5, 2012 – Jun 19, 2013 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past); Oruka Therapeutics, Inc. (Director · Mar 7, 2006 – Feb 5, 2010 · Past) | Director · Mar 24, 2010 – Mar 24, 2010 · Past |
| Ilan Daskal Other companies: Viavi Solutions Inc. (Executive Vice President and Chief Financial Officer · Since at least Nov 7, 2023); PishPosh, Inc. (Director · Mar 18, 2020 – Jul 21, 2022 · Past); SunEdison Inc (EVP & CFO Designee · Apr 1, 2016 – Apr 8, 2016 · Past); TerraForm Power Inc (Director · Mar 30, 2016 – Mar 30, 2016 · Past); Ixia (Director · Jun 26, 2015 – Apr 18, 2017 · Past); Cepheid (EVP, Chief Financial Officer · Apr 9, 2015 – Apr 9, 2015 · Past); International Rectifier Corp (Executive Vice President & CFO · Oct 6, 2011 – Jan 13, 2015 · Past) | EVP, Chief Financial Officer · Apr 6, 2019 – Sep 1, 2023 · Past |
| Gregory K Hinckley Other companies: SI-BONE, Inc. (Director · Since at least Oct 16, 2018); Super Micro Computer, Inc. (Director · Feb 8, 2011 – Feb 10, 2015 · Past); Mentor Graphics Corp (President · Sep 15, 2010 – Mar 30, 2017 · Past); Intermec Inc (Director · May 26, 2010 – Sep 17, 2013 · Past) | Director · Since at least Apr 25, 2017 |
| Andrew J Last Other companies: Insight Molecular Diagnostics Inc. (Director · Since at least Dec 30, 2015); Precigen, Inc. (Chief Operating Officer · Aug 29, 2016 – Nov 13, 2017 · Past); Affymetrix Inc (EVP, Chief Operating Officer · Feb 24, 2010 – Mar 31, 2016 · Past) | EVP, Chief Operating Officer · Apr 22, 2019 – Sep 6, 2024 · Past |
| Jeffrey L. Edwards Other companies: Kyntra Bio, Inc. (Director · Since at least Oct 28, 2015); Lifecore Biomedical, Inc. (Director · Oct 14, 2020 – Jul 8, 2024 · Past); Clearside Biomedical Inc (Director · Sep 26, 2018 – Jun 20, 2024 · Past) | Director · Since at least Apr 25, 2017 |
| Deborah Neff Other companies: Cytek Biosciences, Inc. (Lead Independent Director · Since at least Jun 1, 2022); Advanced Medical Optics Inc (Director · May 25, 2006 – May 29, 2008 · Past) | Director · Oct 26, 2011 – Oct 26, 2011 · Past |
| Joel McComb Other companies: Avid Bioservices Inc (Director · Nov 27, 2017 – Dec 14, 2018 · Past); Illumina, Inc. (Sr VP & General Manager · Mar 17, 2008 – Jan 28, 2010 · Past) | Director · Jul 23, 2014 – Jul 23, 2014 · Past |
| Roop Kalyan Lakkaraju Other companies: Infinera Corporation (Director · May 19, 2022 – Feb 28, 2025 · Past); Benchmark Electronics, Inc. (EVP, Chief Financial Officer · Feb 22, 2022 – Feb 23, 2024 · Past) | EVP, Chief Financial Officer · Since at least Apr 15, 2024 |
| Annette Tumolo Other companies: Telesis Bio, Inc. (Director · Jul 6, 2023 – Jul 6, 2023 · Past) | Executive Vice President · Sep 18, 2017 – Nov 11, 2021 · Past |
| Jonathan P DiVincenzo Other companies: Labcorp Holdings Inc. (EVP, Pres, Central Labs & Intl · May 1, 2023 – Mar 27, 2024 · Past) | President & COO · Since at least Sep 9, 2024 |
All 32 people
| Person | Seat |
|---|---|
| Melinda Litherland Pei Other companies: Rapid Micro Biosystems, Inc. (Director · Since at least Jul 14, 2021) | Director · Since at least Apr 25, 2017 |
| Ajit Ramalingam | SVP, Chief Accounting Officer · Apr 29, 2022 – Sep 1, 2023 · Past |
| Alice N Schwartz | Director · Dec 3, 2019 – Nov 9, 2021 · Past |
| Anna Gralinska | Corporate Communications · Since at least Sep 16, 2026 |
| Arnold A Pinkston | Director · Since at least Sep 6, 2024 |
| Colleen Corey | EVP, Global Human Resources · Since at least Apr 26, 2023 |
| Dara Wright | EVP, President, CDG · Dec 16, 2019 – Dec 16, 2023 · Past |
| Diane Dahowski | EVP, Global Supply Chain · Apr 27, 2022 – Sep 1, 2023 · Past |
| Edward Chung | Investor Relations · Since at least Feb 12, 2026 |
| Eva Anette Engelhardt | EVP, President, CDG · Since at least Jun 10, 2024 |
| James Barry | EVP, President, LSG · Since at least May 1, 2024 |
| James Bennett | Director · Mar 31, 2006 – Nov 19, 2010 · Past |
| Michael Crowley | EVP, GBL Commercial Operations · Nov 28, 2023 – Mar 14, 2025 · Past |
| Norman Schwartz | CEO · Since at least Aug 4, 2026 |
| Rajat Mehta | EVP, GBL Commercial Operations · Since at least Aug 4, 2025 |
| Ronald W Hutton | Vice President and Treasurer · Jun 10, 2010 – Sep 11, 2020 · Past |
| Ruben Argueta | Investor Relations · Since at least Sep 16, 2026 |
| Sanford Wadler | VP, General Counsel, Secretary · Jun 10, 2009 – Nov 4, 2012 · Past |
| Schwartz Allison | Director · Since at least Apr 26, 2022 |
| Sedat Evran | EVP, Global Supply Chain · Since at least Sep 5, 2023 |
| Tania Devilliers | INT PRIN ACCTG OFC · Sep 19, 2023 – Sep 19, 2023 · Past |
| Timothy S Ernst | EVP, General Counsel & Sec · Jun 6, 2016 – Mar 8, 2024 · Past |
Log in to ask 6ix AI your own questions about Bio-Rad Laboratories, Inc.